ANI Pharmaceuticals Reports Strong Q4 Earnings Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy ANIP?
Source: Benzinga
- Earnings Beat: ANI Pharmaceuticals reported adjusted earnings of $2.33 per share for Q4, a 43% increase from $1.63 a year ago, surpassing the consensus estimate of $2.00, indicating a significant improvement in profitability.
- Significant Revenue Growth: Total net revenues for Q4 reached $247.1 million, marking a 29.6% year-over-year increase and exceeding the consensus estimate of $231.53 million, reflecting strong performance in the rare disease segment.
- Rare Disease Segment Surge: The Rare Disease segment saw a remarkable 50.8% growth, contributing $131.3 million to overall revenue, indicating sustained demand for products like Cortrophin Gel and driving overall performance.
- Optimistic Future Outlook: The company expects to exceed $1 billion in sales for 2026, with the Rare Disease segment projected to represent 60% of total revenue, showcasing long-term growth potential and further solidifying its market position in this area.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANIP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANIP
Wall Street analysts forecast ANIP stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 80.920
Low
100.00
Averages
115.00
High
124.00
Current: 80.920
Low
100.00
Averages
115.00
High
124.00
About ANIP
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ANI Pharmaceuticals Launches Pimozide Tablets
- Product Launch: ANI Pharmaceuticals has announced the launch of Pimozide Tablets in 1 mg and 2 mg doses, serving as the generic version of the reference listed drug Orap®, marking a significant expansion in the generic drug market.
- Market Exclusivity: The product has been granted 180-day CGT exclusivity, which is expected to reduce market competition and help ANI solidify its position in the generic drug sector.
- Sales Potential: According to February 2026 IQVIA data, annual sales for Pimozide Tablets in the U.S. are approximately $3.1 million, indicating strong potential profitability for the product in the market.
- Company Strategy: ANI Pharmaceuticals is committed to achieving sustainable growth through the development and commercialization of innovative therapeutics, particularly in its Rare Disease and Generics businesses, thereby enhancing its competitiveness in the biopharmaceutical industry.
See More
ANI Pharmaceuticals Launches Pimozide Tablets
- Product Launch: ANI Pharmaceuticals has announced the launch of Pimozide Tablets in 1 mg and 2 mg dosages, serving as the generic version of the reference listed drug Orap, which is expected to create new revenue streams for the company.
- Market Potential: According to February 2026 IQVIA data, annual U.S. sales for Pimozide Tablets are approximately $3.1 million, indicating significant potential profitability for this product in the market.
- Competitive Advantage: CEO Nikhil Lalwani emphasized the company's commitment to introducing limited competition products to provide more generic options, thereby enhancing accessibility for customers and patients.
- Stock Performance: In pre-market trading, ANI Pharmaceuticals' stock rose by 1.80% to $82.38, reflecting positive market sentiment regarding the new product launch.
See More
ANI Pharmaceuticals Launches Carbamazepine Extended-Release Capsules
- New Product Launch: ANI Pharmaceuticals has announced the launch of carbamazepine extended-release capsules, a generic version of the anticonvulsant Carbatrol, which is expected to meet market demand for seizure prevention and trigeminal neuralgia treatment, thereby expanding its product portfolio.
- Market Potential: As of February 2026, annual sales for carbamazepine extended-release capsules in the U.S. reached $65 million, indicating significant economic potential for the drug that could enhance ANI's revenue.
- FDA Approval Progress: ANI Pharmaceuticals received FDA approval on April 8, 2026, for the abbreviated new drug application for isosorbide mononitrate tablets, further strengthening its competitive position in the cardiovascular drug market.
- Stock Market Performance: Despite ANI Pharmaceuticals' stock closing at $78.31, down 0.06% on the launch day, the introduction of new products may drive future stock price recovery and bolster investor confidence.
See More
ANI Pharmaceuticals Launches Isosorbide Mononitrate to Enhance Market Competitiveness
- New Drug Launch: ANI Pharmaceuticals has received FDA final approval to launch Isosorbide Mononitrate Tablets USP in 10 mg and 20 mg, marking the company's efforts to introduce limited-competition products into the market.
- Strong Financial Performance: In Q4 2025, ANI reported revenues of $247.1 million, a 29.6% increase from $190.6 million the previous year, indicating robust growth momentum in the market.
- Optimistic Future Outlook: The company projects total net revenue for 2026 to be between $1.055 billion and $1.115 billion, up from $883 million in 2025, reflecting a growth rate of 19% to 26% driven by sustained market demand and product innovation.
- Stable Stock Performance: ANI Pharmaceuticals' stock has traded between $56.71 and $99.50 over the past year, closing at $79.01 on Wednesday, down 0.58%, indicating market interest in its new product offerings.
See More
ANI Pharmaceuticals Receives FDA Approval for New Drug Launch
- FDA Approval Announcement: ANI Pharmaceuticals has received final FDA approval for its Isosorbide Mononitrate Tablet USP, launching both 10mg and 20mg versions, which signifies the company's expansion into the limited-competition market and is expected to enhance its market share in cardiovascular medications.
- Product Launch Strategy: CEO Nikhil Lalwani stated that this launch not only showcases ANI's strengths in R&D and operational execution but also emphasizes the company's commitment to continuously introducing new products to meet patient needs, which is anticipated to boost customer loyalty.
- Diversified Business Focus: ANI Pharmaceuticals is committed to sustainable growth across its Rare Disease, Generics, and Brands businesses, particularly in innovative products within ophthalmology, rheumatology, nephrology, neurology, and pulmonology, which is expected to provide long-term revenue growth potential for the company.
- Market Competition Challenges: Despite the positive outlook from the new drug launch, the company faces pressures from competitors and risks associated with FDA policy changes, which could impact product market acceptance and profitability, necessitating ongoing market monitoring to adjust strategies accordingly.
See More
ANI Pharmaceuticals Executive Sells Shares
- Insider Stock Sale: Thomas Rowland, an executive at ANI Pharmaceuticals, sold 4,772 shares in an open-market transaction on March 11, 2026, totaling $357,471, indicating a trend of insider selling within the company.
- Ownership Stake Change: Following this transaction, Rowland's direct ownership decreased by 11%, leaving him with 38,730 shares, which may reflect concerns about the company's future growth prospects.
- Transaction Price Analysis: The shares were sold at $74.91 each, approximately 3.8% above the market price of $72.17 as of March 17, 2026, suggesting that the executive capitalized on a favorable market condition.
- Company Financial Performance: ANI Pharmaceuticals reported record revenue of $883.4 million in 2025, a 43.8% year-over-year increase, highlighting strong growth in its rare disease segment, although insider selling may raise market concerns about the company's trajectory.
See More
ANI Pharmaceuticals Launches Pimozide Tablets
- Product Launch: ANI Pharmaceuticals has announced the launch of Pimozide Tablets in 1 mg and 2 mg doses, serving as the generic version of the reference listed drug Orap®, marking a significant expansion in the generic drug market.
- Market Exclusivity: The product has been granted 180-day CGT exclusivity, which is expected to reduce market competition and help ANI solidify its position in the generic drug sector.
- Sales Potential: According to February 2026 IQVIA data, annual sales for Pimozide Tablets in the U.S. are approximately $3.1 million, indicating strong potential profitability for the product in the market.
- Company Strategy: ANI Pharmaceuticals is committed to achieving sustainable growth through the development and commercialization of innovative therapeutics, particularly in its Rare Disease and Generics businesses, thereby enhancing its competitiveness in the biopharmaceutical industry.
See More
ANI Pharmaceuticals Launches Pimozide Tablets
- Product Launch: ANI Pharmaceuticals has announced the launch of Pimozide Tablets in 1 mg and 2 mg dosages, serving as the generic version of the reference listed drug Orap, which is expected to create new revenue streams for the company.
- Market Potential: According to February 2026 IQVIA data, annual U.S. sales for Pimozide Tablets are approximately $3.1 million, indicating significant potential profitability for this product in the market.
- Competitive Advantage: CEO Nikhil Lalwani emphasized the company's commitment to introducing limited competition products to provide more generic options, thereby enhancing accessibility for customers and patients.
- Stock Performance: In pre-market trading, ANI Pharmaceuticals' stock rose by 1.80% to $82.38, reflecting positive market sentiment regarding the new product launch.
See More
ANI Pharmaceuticals Launches Carbamazepine Extended-Release Capsules
- New Product Launch: ANI Pharmaceuticals has announced the launch of carbamazepine extended-release capsules, a generic version of the anticonvulsant Carbatrol, which is expected to meet market demand for seizure prevention and trigeminal neuralgia treatment, thereby expanding its product portfolio.
- Market Potential: As of February 2026, annual sales for carbamazepine extended-release capsules in the U.S. reached $65 million, indicating significant economic potential for the drug that could enhance ANI's revenue.
- FDA Approval Progress: ANI Pharmaceuticals received FDA approval on April 8, 2026, for the abbreviated new drug application for isosorbide mononitrate tablets, further strengthening its competitive position in the cardiovascular drug market.
- Stock Market Performance: Despite ANI Pharmaceuticals' stock closing at $78.31, down 0.06% on the launch day, the introduction of new products may drive future stock price recovery and bolster investor confidence.
See More
ANI Pharmaceuticals Launches Isosorbide Mononitrate to Enhance Market Competitiveness
- New Drug Launch: ANI Pharmaceuticals has received FDA final approval to launch Isosorbide Mononitrate Tablets USP in 10 mg and 20 mg, marking the company's efforts to introduce limited-competition products into the market.
- Strong Financial Performance: In Q4 2025, ANI reported revenues of $247.1 million, a 29.6% increase from $190.6 million the previous year, indicating robust growth momentum in the market.
- Optimistic Future Outlook: The company projects total net revenue for 2026 to be between $1.055 billion and $1.115 billion, up from $883 million in 2025, reflecting a growth rate of 19% to 26% driven by sustained market demand and product innovation.
- Stable Stock Performance: ANI Pharmaceuticals' stock has traded between $56.71 and $99.50 over the past year, closing at $79.01 on Wednesday, down 0.58%, indicating market interest in its new product offerings.
See More
ANI Pharmaceuticals Receives FDA Approval for New Drug Launch
- FDA Approval Announcement: ANI Pharmaceuticals has received final FDA approval for its Isosorbide Mononitrate Tablet USP, launching both 10mg and 20mg versions, which signifies the company's expansion into the limited-competition market and is expected to enhance its market share in cardiovascular medications.
- Product Launch Strategy: CEO Nikhil Lalwani stated that this launch not only showcases ANI's strengths in R&D and operational execution but also emphasizes the company's commitment to continuously introducing new products to meet patient needs, which is anticipated to boost customer loyalty.
- Diversified Business Focus: ANI Pharmaceuticals is committed to sustainable growth across its Rare Disease, Generics, and Brands businesses, particularly in innovative products within ophthalmology, rheumatology, nephrology, neurology, and pulmonology, which is expected to provide long-term revenue growth potential for the company.
- Market Competition Challenges: Despite the positive outlook from the new drug launch, the company faces pressures from competitors and risks associated with FDA policy changes, which could impact product market acceptance and profitability, necessitating ongoing market monitoring to adjust strategies accordingly.
See More
ANI Pharmaceuticals Executive Sells Shares
- Insider Stock Sale: Thomas Rowland, an executive at ANI Pharmaceuticals, sold 4,772 shares in an open-market transaction on March 11, 2026, totaling $357,471, indicating a trend of insider selling within the company.
- Ownership Stake Change: Following this transaction, Rowland's direct ownership decreased by 11%, leaving him with 38,730 shares, which may reflect concerns about the company's future growth prospects.
- Transaction Price Analysis: The shares were sold at $74.91 each, approximately 3.8% above the market price of $72.17 as of March 17, 2026, suggesting that the executive capitalized on a favorable market condition.
- Company Financial Performance: ANI Pharmaceuticals reported record revenue of $883.4 million in 2025, a 43.8% year-over-year increase, highlighting strong growth in its rare disease segment, although insider selling may raise market concerns about the company's trajectory.
See More
